{"title":"药物化学发展趋势。","authors":"K. Chou","doi":"10.3390/MOL2NET-03-04615","DOIUrl":null,"url":null,"abstract":"The Society for Medicines Research held a meeting on Trends in Medicinal Chemistry on November 30, 2000, in Stevenage, U.K., with the goal of alerting researchers to emerging areas of chemistry and novel classes of compounds likely to lead to new approaches to the treatment of disease. Speakers from nine pharmaceutical companies described areas of research that included phosphodiesterase inhibitors, adenosine receptor ligands, VEGF RTK inhibitors, RNA-protein interaction inhibitors, NMT inhibitors, anti-HCV agents and antidepressants.","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"1 1","pages":"628-33"},"PeriodicalIF":0.0000,"publicationDate":"2017-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Trends in medicinal chemistry.\",\"authors\":\"K. Chou\",\"doi\":\"10.3390/MOL2NET-03-04615\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The Society for Medicines Research held a meeting on Trends in Medicinal Chemistry on November 30, 2000, in Stevenage, U.K., with the goal of alerting researchers to emerging areas of chemistry and novel classes of compounds likely to lead to new approaches to the treatment of disease. Speakers from nine pharmaceutical companies described areas of research that included phosphodiesterase inhibitors, adenosine receptor ligands, VEGF RTK inhibitors, RNA-protein interaction inhibitors, NMT inhibitors, anti-HCV agents and antidepressants.\",\"PeriodicalId\":11325,\"journal\":{\"name\":\"Drug news & perspectives\",\"volume\":\"1 1\",\"pages\":\"628-33\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug news & perspectives\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/MOL2NET-03-04615\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug news & perspectives","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/MOL2NET-03-04615","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Society for Medicines Research held a meeting on Trends in Medicinal Chemistry on November 30, 2000, in Stevenage, U.K., with the goal of alerting researchers to emerging areas of chemistry and novel classes of compounds likely to lead to new approaches to the treatment of disease. Speakers from nine pharmaceutical companies described areas of research that included phosphodiesterase inhibitors, adenosine receptor ligands, VEGF RTK inhibitors, RNA-protein interaction inhibitors, NMT inhibitors, anti-HCV agents and antidepressants.